The products included on the list were - Efavirenz tablets(600 mg), Lamivudine oral solution (10 mg/ml), Lamivudine and Zidovudine tablets (150/300 mg), Stavudine capsules(30 mg), Stavudine capsules (40 mg), Zidovudine oral solution (50 mg/5 ml), the company informed the Bombay Stock Exchange.
Following this inclusion the total number of the company's ARV products on WHO's pre-qualification list has gone up to ten, it said.
An important first line agent in the treatment of HIV, AIDS, Efavirenz tablets, have appeared for the first on the prequalification list of WHO, it added. Previously Zidovudine tablets (300 mg), Lamivudine tablets (150 mg), Lamivudine tablets (300 mg) and (Nevirapine tablets (200 mg), had been included in the list.
© 2026